NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.620
+0.020 (1.25%)
Jul 31, 2026, 4:00 PM EDT - Market closed
NervGen Pharma Cash Flow Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -41.84 | -44.12 | -24.25 | -22.38 | -20.72 | -12.73 |
Depreciation & Amortization | 0.06 | 0.06 | 0.08 | 0.15 | 0.12 | 0.04 |
Loss (Gain) From Sale of Assets | - | - | 0.01 | - | - | - |
Stock-Based Compensation | 4.89 | 5.39 | 6.04 | 6.04 | 2.77 | 4.02 |
Other Operating Activities | 14.86 | 18.51 | 0.44 | 5.14 | -2.07 | -0.03 |
Change in Accounts Receivable | 0.24 | 0.33 | -0.17 | -0.22 | 0.04 | -0 |
Change in Accounts Payable | 1.44 | -0.27 | 1.23 | -0.07 | 2.32 | 0.32 |
Change in Other Net Operating Assets | -3.22 | 0.59 | -0.22 | 0.06 | -0.24 | 0.11 |
Operating Cash Flow | -23.58 | -19.5 | -16.84 | -11.3 | -17.78 | -8.27 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | - | - | -0.01 | -0.02 | -0 |
Sale of Property, Plant & Equipment | - | - | - | 0 | - | - |
Sale (Purchase) of Intangibles | - | - | - | -0.14 | - | -0.04 |
Other Investing Activities | 0.08 | 0.1 | 0.06 | - | - | - |
Investing Cash Flow | 0.08 | 0.1 | 0.06 | -0.14 | -0.02 | -0.05 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -0.1 | -0.1 | -0.1 | -0.08 | - |
Net Debt Issued (Repaid) | -0.08 | -0.1 | -0.1 | -0.1 | -0.08 | - |
Issuance of Common Stock | 25.84 | 24.76 | 24.43 | 0.87 | 22.85 | 21.28 |
Other Financing Activities | -0.48 | -0.89 | -1.63 | - | -0.13 | -1.67 |
Financing Cash Flow | 25.27 | 23.76 | 22.7 | 0.77 | 22.64 | 19.61 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.31 | 0.44 | -0.31 | -0.12 | 0.69 | 0.03 |
Net Cash Flow | 2.09 | 4.8 | 5.61 | -10.79 | 5.52 | 11.33 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -23.58 | -19.5 | -16.84 | -11.3 | -17.81 | -8.27 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.32 | -0.27 | -0.25 | -0.19 | -0.34 | -0.21 |
Levered Free Cash Flow | -13.71 | -6.29 | -8.74 | -0.3 | -3 | -3.56 |
Unlevered Free Cash Flow | -13.71 | -6.29 | -8.74 | -0.3 | -2.67 | -3.56 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Change in Working Capital | -1.54 | 0.66 | 0.84 | -0.24 | 2.11 | 0.43 |